RM 1929

Drug Profile

RM 1929

Alternative Names: RM1929

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Aspyrian Therapeutics
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Head and neck cancer

Most Recent Events

  • 01 Jun 2015 Phase-I clinical trials in Head and neck cancer (Recurrent, Second-line therapy or greater) in USA (Parenteral) (NCT02422979)
  • 12 May 2015 The US FDA approves IND application for RM 1929 in Head and Neck Cancer
  • 27 Apr 2015 Aspyrian Therapeutics plans a phase I trial in Head and Neck cancer (Recurrent, Second-line therapy or greater) in USA (NCT02422979)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top